#United States #WATS3D #Dan Lister #Arkansas Heartburn #Suffern, NY

WATS3D Assay: Setting a New Benchmark in GI Diagnostics

The Arkansas Heartburn Treatment Center has been at the forefront of esophageal care for almost a decade by utilizing the innovative WATS3D assay. This groundbreaking tool is designed to enhance the detection of early-stage esophageal diseases, which is crucial as the incidence of esophageal cancer continues to rise alarmingly across the United States.

Rising Esophageal Cancer Rates

According to projections from the National Institute of Health (NIH), about 17,650 new cases of esophageal cancer are diagnosed each year in the U.S., with Arkansas notably exceeding the average incidence rate at 5 per 100,000 residents. This underscores the urgent need for effective screening and public awareness regarding this potentially fatal illness.

The Role of WATS3D in Early Detection

Dr. Dan Lister, a passionate advocate for early detection at the Arkansas Heartburn Treatment Center, has observed firsthand the positive impact of advanced technology on patient outcomes. He highlights how the WATS3D assay has revolutionized their approach by enabling the identification of high-grade dysplasia in patients who had previously received negative endoscopic evaluations. Dr. Lister asserts, "This advanced precancer detection capability allows us to take swift action, potentially saving lives that might otherwise be at risk."

WATS3D, which stands for Wide Area Transepithelial Sampling with 3D Analysis, employs unique brush collection technology paired with advanced computer imaging and artificial intelligence. This combination has proven so effective that over 400,000 tests have been conducted, leading to over 22 published studies. A noteworthy study involving 24,000 patients demonstrated that the WATS3D assay identified 46% more cases of Barrett's esophagus than traditional forceps biopsy methods.

A Standard of Care for Esophageal Health

As a direct result of Dr. Lister's commitment and the efficacy of WATS3D, many healthcare practices are beginning to adopt it as their standard of care for detecting esophageal diseases. Tom Bartel, EVP Sales at CDx Diagnostics, emphasizes the significance of these results, stating, "When physicians see the results with their own patients, they comprehend its true value in detecting and preventing esophageal cancer."

The Mission of CDx Diagnostics

CDx Diagnostics, the company behind the WATS3D technology, aims to empower physicians with this innovative diagnostic platform to prevent esophageal cancer, one patient at a time. By leveraging advanced imaging, artificial intelligence, molecular biology, and 3D cytopathology, the WATS3D assay is capable of detecting precancerous changes more accurately than traditional methods. This pioneering approach has transformed the landscape of esophageal diagnostics, contributing to improved patient care outcomes.

For further details on the WATS3D assay and its capabilities, visit CDx Diagnostics.

WATS3D sets a new diagnostic standard that not only enhances the quality of esophageal healthcare but also emphasizes the importance of proactive screening and early intervention in the fight against esophageal cancer.